Disposition of 18860 shares by Ragosa Mark of Kiniksa Pharmaceuticals at 11.1 subject to Rule 16b-3

KNSA Stock  USD 20.01  0.10  0.50%   
About 62% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Kiniksa Pharmaceuticals Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 18860 share option at 11.1 of Kiniksa Pharmaceuticals by Ragosa Mark on 9th of December 2024. This event was filed by Kiniksa Pharmaceuticals with SEC on 2024-12-09. Statement of changes in beneficial ownership - SEC Form 4

Kiniksa Pharmaceuticals Fundamental Analysis

We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Kiniksa Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Kiniksa Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Kiniksa Pharmaceuticals Related Equities

SPROSpero Therapeutics   9.57   
0%
100.0%
PHATPhathom Pharmaceuticals   9.07   
0%
94.0%
LYRALyra Therapeutics   5.56   
0%
58.0%
NVCTNuvectis Pharma   3.98   
0%
41.0%
KRONKronos Bio   2.17   
0%
22.0%
VTYXVentyx Biosciences   2.15   
0%
22.0%
BOLTBolt Biotherapeutics   1.96   
0%
20.0%
ACLXArcellx   1.86   
0%
19.0%
CHRSCoherus BioSciences   1.36   
0%
14.0%
GOSSGossamer Bio   1.19   
0%
12.0%
DAWNDay One   0.23   
2.0%
0%
LRMRLarimar Therapeutics   1.00   
10.0%
0%
COGTCogent Biosciences   1.53   
15.0%
0%
GPCRStructure Therapeutics   1.69   
17.0%
0%
NUVLNuvalent   2.14   
22.0%
0%
KURAKura Oncology   3.45   
36.0%
0%
REPLReplimune   4.14   
43.0%
0%
CGEMCullinan Oncology   6.82   
71.0%
0%

Complementary Tools for Kiniksa Stock analysis

When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments